代谢功能障碍相关脂肪性肝病与更高骨密度相关:NHANES研究结果
基于NHANES 2005-2010、2013-2014及2017-2018周期6470名18岁及以上美国成年人数据,采用横断面设计分析MASLD与骨密度的关联。多变量调整后,MASLD患者股骨颈骨密度(β=0.0238;95%CI 0.0154-0.0321)和全股骨骨密度(β=0.0332;95%CI 0.0244-0.0419)均高于无MASLD者,且MASLD与骨质疏松风险降低显著相关。
要点
- MASLD患者股骨颈和全股骨骨密度均高于无MASLD者。
- BMI≥25、糖尿病、高血压、高脂血症亚组亦显示股骨骨密度更高。
- MASLD与骨质疏松风险降低显著相关。
核心结论
- MASLD参与者骨密度高于无MASLD者,且MASLD与骨质疏松风险降低显著相关。
研究设计与样本
- 横断面研究,纳入NHANES 2005-2010、2013-2014及2017-2018周期6470名18岁及以上参与者。
- MASLD依据Delphi共识诊断标准定义,采用多变量线性回归分析股骨颈和全股骨骨密度,逻辑回归分析骨质疏松。
主要发现
- 6470名参与者平均年龄53.16±17.27岁,男性占49.54%,23.52%符合MASLD标准。
- 多变量调整后,MASLD者股骨颈骨密度β=0.0238(95%CI 0.0154-0.0321),全股骨骨密度β=0.0332(95%CI 0.0244-0.0419),均高于无MASLD者。
- 亚组分析中,BMI≥25 kg/m²、糖尿病、高血压、高脂血症者多变量调整后股骨骨密度亦更高。
- 多变量逻辑回归显示MASLD与骨质疏松风险降低显著相关。
关键数值与推荐
- MASLD诊断依据Delphi共识标准。
- 骨密度结局为股骨颈和全股骨骨密度,骨质疏松为逻辑回归结局。
临床怎么用
- 在评估骨密度和骨质疏松风险时,可关注MASLD及其心血管代谢组分的存在。
- MASLD患者可能呈现较高骨密度,解读骨密度结果时需结合代谢状态综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We used data from the National Health and Nutrition Examination Survey (NHANES) to investigate the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and bone mineral density (BMD) among U.S. adults. Our findings indicated that participants with MASLD had higher BMD than those without MASLD. INTRODUCTION: Given the stigma associated with the term "NAFLD," experts participating in a Delphi consensus proposed renaming the condition "MASLD". Nevertheless, the association between MASLD and BMD remains unclear. This study aimed to investigate the relationship between MASLD and BMD. METHODS: A cross-sectional study was conducted among 6470 participants aged 18 years or older using data from the 2005 to 2010, 2013 to 2014, and 2017 to 2018 cycles of the NHANES. MASLD was defined according to diagnostic criteria established through a Delphi consensus. Multivariable linear regression analyses were performed to evaluate the associations of MASLD with femoral neck and total femur BMD, while logistic regression analysis was used to investigate the association between MASLD and osteoporosis. RESULTS: Among the 6470 participants, the mean age was 53.16 ± 17.27 years, 49.54% were male, and 23.52% met the criteria for MASLD. After multivariable adjustment, participants with MASLD had higher femoral neck BMD (β = 0.0238; 95% CI, 0.0154-0.0321) and total femur BMD (β = 0.0332; 95% CI, 0.0244-0.0419) than those without MASLD. In subgroup analyses, participants with individual cardiometabolic components of MASLD, including BMI ≥ 25 kg/m², diabetes, hypertension, and hyperlipidemia, also exhibited higher femoral BMD after multivariable adjustment. Moreover, multivariable logistic regression analysis indicated that MASLD was significantly associated with lower odds of osteoporosis. CONCLUSIONS: Our findings suggest that participants with MASLD have higher BMD compared to those without MASLD.
引用
- Liu J, Zhan H, Yi Z, et al. Metabolic dysfunction-associated steatotic liver disease is associated with higher bone mineral density: results from NHANES. Osteoporos Int. 2026. PMID: 42859223. doi:10.1007/s00198-026-08226-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。